Abbott Labs SEC Filings

Abbott Laboratories executive John A. McCoy Jr., Vice President and Controller, reported equity awards on February 24, 2026. He acquired an employee stock option for 22,151 options with no purchase price, which vests in three annual installments beginning in 2027. He also received a performance-based restricted stock award of 5,373 common shares that can vest over three years if Abbott meets a minimum return-on-equity target, with shares eligible to be withheld for taxes. Separately, he reported 58 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust as of that date.

Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades. He acquired 344,066 options with a zero-dollar grant price under the Abbott Laboratories 2017 Incentive Stock Program, scheduled to become exercisable in three equal annual installments starting on February 24, 2027.

Ford also received a performance-based restricted stock award of 83,464 common shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target. An additional 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.

Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories executive Lisa D. Earnhardt, EVP and Group President, reported equity awards on February 24, 2026. She was granted stock options covering 111,533 options and a performance-based restricted stock award of 27,056 common shares under the Abbott Laboratories 2017 Incentive Stock Program.

The restricted stock award has a three-year term, with no more than one-third vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for taxes. The stock option becomes exercisable in increments of 37,177 and 37,178 shares on February 24, 2027, February 24, 2028, and February 24, 2029.

Cushman Elizabeth C. reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories executive Elizabeth C. Cushman, EVP, GC and Secretary, reported equity awards on February 24, 2026. She received an employee stock option for 61,964 options under the Abbott 2017 Incentive Stock Program, exercisable in three annual installments starting in 2027. She was also granted 15,031 performance-based restricted shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target and allowing shares to be withheld for taxes.

ABBOTT LABORATORIES executive Philip P. Boudreau, EVP and CFO, reported equity awards. On February 24, 2026, he acquired an employee stock option for 115,413 shares with no exercise price shown here, granted under the Abbott Laboratories 2017 Incentive Stock Program and scheduled to become exercisable in three equal annual installments beginning February 24, 2027.

On the same date, he also received a performance-based restricted stock award of 27,997 common shares without par value, with a three‑year term and no more than one‑third vesting in any year, contingent on Abbott reaching a minimum return on equity target and allowing share withholding for taxes. Following these awards, he directly owned 78,613 common shares366 shares through an Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

Abbott Laboratories entered into a pricing agreement to issue and sell $20,000,000,000 aggregate principal amount of senior notes across eight tranches, including Floating Rate Notes due 2029 and Fixed Rate Notes with coupons from 3.700% to 5.600% maturing between 2029 and 2066.

The notes were priced through a syndicate led by major underwriters and offered under Abbott’s effective shelf registration statement via a prospectus and prospectus supplement. Closing of the notes offering is expected on March 9, 2026, subject to customary conditions.

Abbott plans to use the net proceeds, together with cash on hand and/or additional borrowings, to fund consideration for its proposed acquisition of Exact Sciences Corporation, repay certain Exact Sciences indebtedness, cover related fees and expenses, and for general corporate purposes, which may include repayment of other debt.

Abbott Laboratories is offering $20,000,000,000 of notes across eight series to help fund its proposed acquisition of Exact Sciences. The offering includes eight series with aggregate principal amounts by series (Floating Rate and seven Fixed Rate maturities) and net proceeds estimated at $19,825,943,100. The notes will be unsecured, unsubordinated obligations ranking equally with Abbott’s other unsecured debt. Abbott intends to use proceeds, together with cash on hand or borrowings, to fund the Exact Sciences Acquisition, repay certain Exact Sciences indebtedness, pay related fees and expenses, and for general corporate purposes. If the Exact Sciences Acquisition is not consummated by the End Date or Abbott elects not to pursue it, Abbott must redeem outstanding notes at 101% plus accrued interest under a Special Mandatory Redemption provision.

Abbott Laboratories is offering multiple series of unsecured notes, including a floating-rate series tied initially to Compounded SOFR, and several fixed-rate series. The company intends to use net proceeds, together with cash on hand or borrowings, to fund the proposed acquisition of Exact Sciences for $105.00 per Exact Sciences share.

The prospectus supplement imposes a Special Mandatory Redemption if the Exact Sciences acquisition is not consummated by the date that is five business days after February 17, 2027 (or any later End Date agreed by the parties), requiring redemption at 101% of principal plus accrued interest. The notes will be unsecured and rank equally with Abbott’s other unsecured and unsubordinated debt.

Abbott Laboratories registers securities on a shelf prospectus under Form S-3, permitting the sale of debt securities, common shares, preferred shares, depositary shares, warrants, purchase contracts and units.

The prospectus is dated February 23, 2026 and states offerings may occur "From time to time after the effective date of this Registration Statement." As context, Abbott reports 1,737,682,887 common shares outstanding as of January 31, 2026 and 2,400,000,000 authorized common shares.